OverviewSuggest Edit

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of hepatorenal syndrome.
TypePublic
Founded1989
HQSan Diego, US
Websitelajollapharmaceutical.com

Latest Updates

Employees (est.) (Feb 2020)90(-46%)
Revenue (FY, 2019)$23.1 M(+130%)
Share Price (Sept 2020)$5 (+11%)
Cybersecurity ratingAMore

Key People/Management at La Jolla Pharmaceutical Company

Lakhmir S. Chawla

Lakhmir S. Chawla

Chief Medical Officer
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer
Craig Johnson

Craig Johnson

Director
David Ramsay

David Ramsay

Director
James M. Rolke

James M. Rolke

Chief Scientific Officer
Robert Rosen

Robert Rosen

Director
Show more

La Jolla Pharmaceutical Company Office Locations

La Jolla Pharmaceutical Company has an office in San Diego
San Diego, US (HQ)
4550 Towne Centre Ct
Show all (1)

La Jolla Pharmaceutical Company Financials and Metrics

La Jolla Pharmaceutical Company Revenue

La Jolla Pharmaceutical Company's revenue was reported to be $23.05 m in FY, 2019
USD

Revenue (Q2, 2020)

5.8m

Gross profit (Q2, 2020)

5.0m

Gross profit margin (Q2, 2020), %

86.1%

Net income (Q2, 2020)

(15.6m)

EBIT (Q2, 2020)

(12.5m)

Market capitalization (16-Sept-2020)

137.4m

Closing stock price (16-Sept-2020)

5.0

Cash (30-Jun-2020)

68.4m

EV

96.9m
La Jolla Pharmaceutical Company's current market capitalization is $137.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.1m616.0k10.1m23.1m

Cost of goods sold

1.6m2.4m

Gross profit

8.4m20.7m

Gross profit Margin, %

84%90%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

647.0k234.0k253.0k44.0k809.0k1.6m3.5m4.4m5.7m5.7m7.6m5.8m

Cost of goods sold

58.0k129.0k256.0k500.0k551.0k554.0k716.0k808.0k

Gross profit

751.0k1.5m3.2m3.9m5.2m5.2m6.9m5.0m

Gross profit Margin, %

93%92%93%89%90%90%91%86%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.0m3.4m8.6m48.6m126.5m65.7m90.9m172.6m87.8m

Accounts Receivable

1.4m3.0m

Prepaid Expenses

60.0k25.0k43.0k618.0k1.4m3.1m5.1m4.5m

Inventories

2.0m2.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.8m5.5m4.4m3.8m3.4m2.7m1.8m10.7m5.9m3.9m54.1m42.7m36.0m135.1m113.1m100.6m85.0m162.4m141.3m120.8m154.4m241.4m204.3m140.0m123.4m104.8m77.2m68.4m

Accounts Receivable

372.0k1.5m2.0m1.9m1.4m3.6m1.8m

Prepaid Expenses

19.0k9.0k50.0k97.0k40.0k76.0k67.0k47.0k156.0k148.0k153.0k622.0k622.0k484.0k1.4m1.4m1.4m1.7m1.8m1.8m6.3m5.3m5.8m5.1m5.1m4.8m3.4m2.8m

Inventories

820.0k2.0m2.0m1.9m2.0m3.1m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.5m)(7.7m)(17.9m)(21.3m)(41.9m)(78.2m)(114.8m)(199.5m)(116.5m)

Depreciation and Amortization

5.0k17.0k347.0k730.0k1.3m4.4m4.6m

Inventories

(2.0m)(191.0k)

Accounts Payable

31.0k(49.0k)822.0k(104.0k)1.8m3.6m4.8m(2.9m)(4.4m)
USDQ2, 2011

Financial Leverage

-0.9 x
Show all financial metrics

La Jolla Pharmaceutical Company Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

La Jolla Pharmaceutical Company Online and Social Media Presence

Embed Graph

La Jolla Pharmaceutical Company News and Updates

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress

SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results…

La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.

-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-

La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2020

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the thre…

La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium

SAN DIEGO, April 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZ…

La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany

SAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZ…
Show more

La Jolla Pharmaceutical Company Blogs

La Jolla Pharmaceutical Company Announces Management Transition

SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Georg…

La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Geor…

La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the E…

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Progress

SAN DIEGO, CA – August 1, 2019 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for…

La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118 (Artesunate) for the Treatment of Malaria

-Orphan Drug Designation Program offers potentially up to seven years of marketing exclusivity-   -NDA Submission Planned for Fourth Quarter of 2019-   SAN DIEGO, CA – July 23, 2019 – La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of inno…

La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis

– Treatment with LJPC-401 Resulted in Statistically Significant Reduction in Change in Transferrin Saturation (TSAT), the Primary Efficacy Endpoint of the Study, and Frequency of Phlebotomies, a Key Secondary Efficacy Endpoint of the Study – SAN DIEGO, CA – June 6, 2019 – La Jolla Pharmaceutical Com…
Show more

La Jolla Pharmaceutical Company Frequently Asked Questions

  • When was La Jolla Pharmaceutical Company founded?

    La Jolla Pharmaceutical Company was founded in 1989.

  • Who are La Jolla Pharmaceutical Company key executives?

    La Jolla Pharmaceutical Company's key executives are Lakhmir S. Chawla, Dennis Mulroy and Craig Johnson.

  • How many employees does La Jolla Pharmaceutical Company have?

    La Jolla Pharmaceutical Company has 90 employees.

  • What is La Jolla Pharmaceutical Company revenue?

    Latest La Jolla Pharmaceutical Company annual revenue is $23.1 m.

  • What is La Jolla Pharmaceutical Company revenue per employee?

    Latest La Jolla Pharmaceutical Company revenue per employee is $256.2 k.

  • Who are La Jolla Pharmaceutical Company competitors?

    Competitors of La Jolla Pharmaceutical Company include PNP Therapeutics, GLG Pharma and Oncolinx.

  • Where is La Jolla Pharmaceutical Company headquarters?

    La Jolla Pharmaceutical Company headquarters is located at 4550 Towne Centre Ct, San Diego.

  • Where are La Jolla Pharmaceutical Company offices?

    La Jolla Pharmaceutical Company has an office in San Diego.

  • How many offices does La Jolla Pharmaceutical Company have?

    La Jolla Pharmaceutical Company has 1 office.